Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual DiseaseTalha Munir, Peter Hillmen, Ben Kennedy et al.|New England Journal of Medicine|2023Cited by 155
Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor PhenotypesJames Whitworth, Philip Smith, Jose‐Ezequiel Martín et al.|The American Journal of Human Genetics|2018Cited by 73
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic LeukemiaTalha Munir, Peter Hillmen, Sean Girvan et al.|New England Journal of Medicine|2025Cited by 26
Acquired Bruton's tyrosine kinase mutations in patients treated on the ibrutinib and rituximab, ibrutinib alone, and ibrutinib and venetoclax arms of the national multi-centre Phase III FLAIR study in previously untreated CLL patientsCharlotte Evans, Talha Munir, Surita Dalal et al.|Blood|2025Cited by 2
Additional file 1: of Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trialLaura Collett, Peter Hillmen, Dena Howard et al.|Figshare|2017Cited by 0